Adverse Drug Reactions during COVID-19 Treatment: A Comprehensive Analysis Focused on Hospitalized Patients, with the Use of a Survey in Cuba in 2020.

Lizette Gil-Del-ValleRosario Gravier-HernándezWaldemar Baldoquin-RodríguezBeatriz Sierra-VázquezAna Beatriz Perez-DíazPablo Sariol-ResikTatiana Prieto-DominguezMario Manuel Delgado-GuerraJoniel Arnoldo Sánchez-MárquezOlga Elena López-FernándezFaustina Fonseca-BetancourtLiana Valdés-LanzaOdalys Orraca-CastilloXaveer Van Ostade Wim Vanden Berghe Veerle VanlerbergheM Guadalupe Guzmán-Tirado

Published in: Advances in pharmacological and pharmaceutical sciences (2023)

The frequency of ADRs and potential DDI was high compared to their use during nonpandemic times (e.g., for malaria, HIV, or inflammatory diseases). The safety profile of these drugs when used for COVID-19 treatment showed similar characteristics. Comorbidities, age >37 years old, and female sex were associated with ADRs.

Keyphrases

adverse drug
coronavirus disease
sars cov
antiretroviral therapy
hepatitis c virus
human immunodeficiency virus
emergency department
hiv aids
drug induced